Payment overview · 2025
General Payments
$488.57
23 reported records · 6 companies
Healthcare provider profile · identity verified
Zumara Ayers, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Surgical · BRONX, NY · NPI 1285022574
Verified facts
What the public records show
CMS Open Payments records show Zumara Ayers, PA-C received $488.57 in general payments during 2025 across 23 reported records.
Amgen Inc. accounted for 43.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $212.81 | 43.6% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $155.44 | 31.8% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.62 | 10.6% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $26.81 | 5.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.25 | 4.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.64 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $488.57 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $212.81 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $212.81 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $124.05 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.62 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.39 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $26.81 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 233 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
233 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 902 | 277 |
| Metformin Hcl | Metformin Hcl | 569 | 160 |
| Omeprazole | Omeprazole | 434 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 407 | 130 |
| Jardiance | Empagliflozin | 390 | 94 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 360 | 89 |
| Lisinopril | Lisinopril | 297 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 268 | 87 |
| Gabapentin | Gabapentin | 260 | 78 |
| Losartan Potassium | Losartan Potassium | 236 | 82 |
| Ozempic | Semaglutide | 233 | 45 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 226 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 67 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 190 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 181 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 166 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 160 | 51 |
| Famotidine | Famotidine | 159 | 51 |
| Simvastatin | Simvastatin | 141 | 42 |
| Meclizine Hcl | Meclizine Hcl | 140 | 41 |
| Montelukast Sodium | Montelukast Sodium | 137 | 39 |
| Nifedipine Er | Nifedipine | 125 | 35 |
| Ammonium Lactate | Ammonium Lactate | 123 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 115 | 38 |
| Januvia | Sitagliptin Phosphate | 113 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 113 | 33 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 96 | 26 |
| Linzess | Linaclotide | 89 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 28 |
| Single Use Swab | Alcohol Antiseptic Pads | 82 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 81 | 23 |
| Carvedilol | Carvedilol | 80 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 79 | 18 |
| Tradjenta | Linagliptin | 77 | 18 |
| Vascepa | Icosapent Ethyl | 76 | 19 |
| Furosemide | Furosemide | 67 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 17 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 64 | 24 |
| Alendronate Sodium | Alendronate Sodium | 64 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 63 | 15 |
| Meloxicam | Meloxicam | 61 | 33 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 60 | 16 |
| Valsartan | Valsartan | 60 | 16 |
| Ezetimibe | Ezetimibe | 59 | 16 |
| Metformin Hcl Er | Metformin Hcl | 57 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 55 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 21 |
| Glimepiride | Glimepiride | 53 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 13 |
| Valacyclovir | Valacyclovir Hcl | 50 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 17 |
| Eliquis | Apixaban | 47 | 15 |
| Trulicity | Dulaglutide | 47 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 46 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 25 |
| Enalapril Maleate | Enalapril Maleate | 45 | 13 |
| Ibuprofen | Ibuprofen | 45 | 31 |
| Hydrocortisone | Hydrocortisone | 44 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 40 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 13 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Baclofen | Baclofen | 33 | 22 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Clotrimazole | Clotrimazole | 30 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 14 |
| Rybelsus | Semaglutide | 29 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Procto-Med Hc | Hydrocortisone | 27 | 11 |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 16 |
| Promethazine Hcl | Promethazine Hcl | 24 | 18 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 23 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Nystatin | Nystatin | 22 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Naproxen | Naproxen | 18 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Acetic Acid | Acetic Acid | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Sure Comfort Alcohol | Alcohol Antiseptic Pads | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $488.57 · 23 records | Amgen Inc. | AIRSUPRA, BREZTRI, IBSRELA, LEQVIO, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error